moneyheap
PODD · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Insulet Corporation (PODD) stock moving?
Insulet reported a clear Q3 beat on Nov 4: revenue of $842.0M (+19.2%), U.S. Omnipod up 14.7%, international Omnipod up 31.7%, and adjusted EPS of $1.99 versus $1.59 expected. Q4 sales guidance (midpoint about $903M) sits slightly above the $900.5M estimate, while the raised FY2026 sales floor and in-line EPS outlook only roughly match consensus. The stock jumped 6.6% to a $165.02 close on about 2.6M shares, roughly double recent daily volume, but it then gave back the entire gain: $156.12 on Nov 5, a $146.51 low on Nov 6, and $148.06 on Nov 10, about 4% below the $154.86 pre-earnings close. Analysts responded with a wave of target increases (nine updates from $160 to $200, averaging about $173), but most ratings remain Neutral, Equal-Weight or Hold, with only Bernstein and RBC at Outperform. Management also flagged slower growth in 2027 and rival share gains, which caps the long-term case despite the $1B buyback.
News behind the analysis
- Insulet Reports Third Quarter 2026 Financial Results and Announces $1 Billion Share Repurchase ProgramQ3 revenue rose 19.2% to $842.0M, above the guidance range, and a $1B share repurchase program was authorized. Adjusted operating margin reached 22.0%.
- Insulet Q3 Adj. EPS $1.99 Beats $1.59 Estimate, Sales $842.000M Beat $832.685M EstimateAdjusted EPS of $1.99 beat the $1.59 consensus, and sales of $842.0M beat the $832.7M estimate.
- Insulet FY2026 Adj EPS expected to be more than $6.46 vs $6.46 Est; Raises FY2026 Sales Guidance from $3.250B-$3.304B to $3.277B-$3.304B vs $3.289B EstFY2026 adjusted EPS guidance was set at more than $6.46, in line with estimates. The sales guidance floor was raised to $3.277B, with a midpoint close to the $3.289B estimate.
- Insulet Sees Q4 Sales $889.600M-$917.000M vs $900.481M EstQ4 sales guidance of $889.6M to $917.0M has a midpoint of about $903M, slightly above the $900.5M estimate.
- Insulet CEO Sees Slower Growth in 2027, Expects Rivals to Chip Away at Omnipod's Market ShareManagement expects slower growth in 2027 and anticipates competitors will take some Omnipod market share.
- Bernstein Maintains Outperform on Insulet, Raises Price Target to $200Bernstein kept an Outperform rating and raised its price target to $200, the highest among recent updates.
- UBS Maintains Neutral on Insulet, Raises Price Target to $171UBS kept a Neutral rating and raised its price target to $171.
- Barclays Maintains Equal-Weight on Insulet, Raises Price Target to $165Barclays kept an Equal-Weight rating and raised its price target from $150 to $165.
- Truist Securities Reiterates Hold on Insulet, Raises Price Target to $160Truist kept a Hold rating and raised its price target from $153 to $160.
About Insulet Corporation
Insulet is a Massachusetts medical device company that makes the Omnipod, a wearable insulin pump with no tubing. Its Omnipod 5 system connects to continuous glucose monitors and adjusts insulin doses automatically, and it is a leading product in automated insulin delivery, with more than 600,000 users worldwide.
How it makes money
Nearly all of its revenue comes from selling Omnipod products. Customers replace their disposable Pods every few days, so most sales repeat over time. In Q3 2026, revenue was about $842 million. Roughly two-thirds came from the US (about $570 million) and about one-third from international markets (about $266 million). A small amount comes from drug delivery partnerships. In the US, many sales go through pharmacies.
What usually moves PODD
- New Omnipod 5 users, including type 2 diabetes patients
- International expansion and growth rates
- Competition in automated insulin delivery and the Omnipod 6 launch timing
- Gross and operating margin trends
- Insurance and pharmacy coverage of insulin pumps